Metabolic syndrome in liver transplantation: The elephant in the room

Liver Transplantation

Volumn 14, Issue 9, 2008, Pages 1245-1248

  Forman, Lisa M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INSULIN RECEPTOR; INTERFERON; INTERLEUKIN 6; RIBAVIRIN; TUMOR NECROSIS FACTOR; TYROSINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDITORIAL; GRAFT RECIPIENT; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MOLECULAR MECHANICS; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; STEATOSIS; SURGICAL RISK; VIRUS LOAD;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DISEASE PROGRESSION; FIBROSIS; GRAFT SURVIVAL; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 51349125385     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21591     Document Type: Editorial

References (39)

1. Rakela J, Vargas HE. Hepatitis C. Magnitude of the problem. Liver Transpl 2002;8(suppl 1):S3-S6.
2. Gane EJ, Portmarm BC, Naounrov NV, Smith, HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996:334:815-820.
3. Feray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-625.
4. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000:32:852-858.
5. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
6. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transpl 2006;6:449-458.
7. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
8. Charlton M, Seaburg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
9. Rosen HR, Shackleton CR, Higa. L, Gralnek IM, Fanner DA, McDiarmond SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after orthotopic liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
10. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-256.
11. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-726.
12. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV infected liver transplant recipients. Hepatology 2002;36:202-210.
13. Hanouneh IA, Feldstein AE, McCullough, AJ, Miller C, Aucejo F, Yerian L, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008:14:1287-1293.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
15. Hourigan LF, MacDonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219.
16. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-597.
17. Petta S, Camma C, Mario VD, Alessi N, Cabibi D, Caldarella R, Licata A. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008;103:1136-1144.
18. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 2008;82:2606-2612.
19. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848.
20. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130:1636-1642.
21. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C infection in the United States. Ann Int Med 2000;133:592-299.
22. Foxton MR, Quaglia. A, Muiesan P, Heneghan MA, Portmann B, Norris S, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transpl 2006;6:1922-1929.
23. Delgado-Borrego A, Liu YS, Jordan SH, Agrawal S, Zhang H, Christafi M, et al. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl 2008;14:193-201.
24. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C and fibrosis progression. Gut 2003;125:1695-1704.
25. Conjeevarem. HS, Kleiner DE, Everhart JE, Zacks S, Afdhal NH, Wahed AS, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45:80-87.
26. Laryeea M, Watt KD, Molinari M, Walsh MJ, McAlsiter VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpi 2007;13:1109-1114.
27. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Transplantation 1995;60:1057-1060.
28. Munoz SJ, Deems RO, Moritz MJ, Martin P, Jarrell BE, Maddrey WC. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc 1991;23:1480-1483.
29. Saab S, Shpaner A, Zhao Y, Brito I, Durazo F, Han S, et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transpl 2006;6:1890-1895.
30. Chobanian AV, Bakris GL, Black HR, Cushman NC, Green LA, Izzo JL, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-1252.
31. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transpl 2004;4(suppl 7): S13-S53.
32. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
33. John PP, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 2001;34:889-895.
34. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
35. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and cardiovascular mortality in middle aged men. JAMA 2002;288:2709-2716.
36. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. NEJM 2003;348:931-940.
37. Forman LM, Osborne JC, Everson GT. Long-term management after liver transplantation: primary care physician vs. hepatologist? labstracti Am J Transpl 2006;6(suppl): 2031A.
38. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. New Engl J Med 1998;338:1516-1520.
39. Bostom AD, Brown RS, Chavers BM, Coffman TM, Cosio FG, Culver K, et al. Prevention of post-transplant cardiovascular disease-report and recommendations of an ad hoc group. Am J Transpl 2002;2:491-500.